Skip to content

Dietary Protein and Insulin Sensitivity Study

The Effects of Increased Dietary Protein Intake on Insulin Sensitivity in Stable Weight Individuals, Independent of Dietary Content of Carbohydrate and Saturated Fat

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT00508937
Enrollment
660
Registered
2007-07-30
Start date
2007-02-28
Completion date
2009-12-31
Last updated
2020-12-23

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cardiovascular Disease, Dyslipidemia, Insulin Resistance, Metabolic Syndrome, Type 2 Diabetes

Keywords

Diet, Protein, Glucose, Insulin, Cholesterol, Triglycerides, LDL subclasses

Brief summary

The overall objective of the Dietary Protein and Insulin Sensitivity Study is to test the hypothesis that increased protein in a diet with reduced carbohydrate (35% energy) can ameliorate insulin resistance in the absence of weight loss, and that this effect is independent of saturated fat content. Moreover, we will test whether such diets result in beneficial changes in total LDL cholesterol, small, dense LDL, and HDL cholesterol that are also independent of saturated fat intake.

Detailed description

Insulin resistance is a major metabolic disturbance associated with excess adiposity that contributes to atherogenic dyslipidemia and predisposes to both cardiovascular disease and type 2 diabetes mellitus. The effects on insulin resistance of changes in dietary macronutrient composition in the absence of weight loss are poorly understood. To better understand these effects, we will study men and women with insulin resistance after 4 weeks on a basal diet (15% protein, 55% carbohydrate, 30% fat) and 4 weeks after random assignment to the basal diet or one of 4 diets with 35% carbohydrate and either 20% or 30% protein, and either 7% or 15% saturated fat. At the end of each dietary period (4 weeks and 8 weeks), we will draw a blood sample for detailed metabolic measurements and measure insulin sensitivity by the frequently sampled intravenous glucose tolerance test (FSIGT) method. In addition to insulin resistance, we will assess the effect of dietary composition on parameters of atherogenic dyslipidemia.

Interventions

OTHERDiet

15% protein, 55% carbohydrate, 30% fat (7% saturated, 7% polyunsaturated)

Sponsors

Dairy Management Inc.
CollaboratorINDUSTRY
UCSF Benioff Children's Hospital Oakland
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION
Masking
SINGLE (Investigator)

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
Yes

Inclusion criteria

* Body mass index (BMI) ≥ 27 and ≤ 40 kg/m2 * HOMA-IR ≥ 2.5 * Non-smoking * Total cholesterol and LDL cholesterol \<95th percentile for sex and age * Fasting triglycerides \< 500mg/dl * Fasting blood sugar \< 126 * Urinary microalbumin \< 30 mg/L * Normal thyroid stimulating hormone levels * Hematocrit ≥ 36% * Blood pressure \< 150/90 * At least 3 months of a weight-stable state (± 5 lbs) prior to the study. During the study, subjects will be required to maintain their body weight within ± 3% (up to a maximum change of 5 lbs) of their initial weight over the course of any consecutive two weeks after the second week of baseline diet or during the last week of each diet phase

Exclusion criteria

* History of coronary heart disease, cerebrovascular disease, peripheral vascular disease, bleeding disorder, liver or renal disease, diabetes, lung disease, HIV, or cancer (other than skin cancer) in the last 5 years * Use of drugs known to affect lipid metabolism or insulin resistance, hormones, or the blood thinning agent, warfarin * Use of alcohol or dietary supplements during the study * Pregnancy

Design outcomes

Primary

MeasureTime frame
LDL subclasses4wks and 8wks
Triglycerides4wks and 8wks
LDL peak particle size4wks and 8wks
Insulin Sensitivity by Frequently Sampled Intravenous Glucose Tolerance test4wks and 8wks
Total Cholesterol4wks and 8wks
LDL Cholesterol4wks and 8wks
HDL Cholesterol4wks and 8wks

Secondary

MeasureTime frame
Apolipoprotein A14wks and 8wks
Apolipoprotein B4wks and 8wks

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Mar 19, 2026